A global clinical trial testing Immunovant’s injection therapy IMVT-1402 against a placebo in adults with Sjögren’s disease is now recruiting participants and remains on track to provide initial data in 2028. That’s according to a press release from the company, a Roivant subsidiary, announcing Immunovant’s latest…
Dianthus Therapeutics has selected Sjögren’s disease as one of the first three priority indications for the clinical development of DNTH212, its experimental therapy for autoimmune conditions. The treatment is currently being tested in healthy adult volunteers in a China-based Phase 1 clinical trial (NCT07323173), with top-line data…
Efgartigimod, a therapy approved for certain autoimmune diseases, led to higher response rates and greater reductions in certain immune markers than a placebo in adults with Sjögren’s disease, according to final data from a small proof-of-concept clinical trial. Because the Phase 2 study, called RHO (NCT05817669), was not…
Women and men with Sjögren’s disease may experience the condition differently, particularly in the type and severity of symptoms and the organs affected, a study in the Netherlands suggests. While women were more likely to report dry eyes and dry mouth — the hallmark Sjögren’s symptoms — and…
Get regular updates to your inbox.
